– Milestone Payment Triggered by Initiation of Additional Preclinical Studies for REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia – NEW HAVEN, Conn.--(BUSINESS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback